drugset / Trial / NCT04969861
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Phase 2/3
Terminated
1 enrolled
Nektar Therapeutics
Merck Sharp & Dohme LLC · collabSFJ Pharmaceuticals, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab compared with pembrolizumab monotherapy in patients with recurrent or metastatic HNSCC with positive PD-L1 expression (CPS ≥ 1).
Timeline
- Start
- 2022-03-09
- Primary completion
- 2022-04-22
- Completion
- 2022-04-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempegaldesleukin | Protein / enzyme biologic | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |